Christof Vulsteke, MD, Ghent Comprehensive Cancer Centre, Belgium
Unraveling the KEYNOTE-905 Study - Enfortumab Vedotin Combined with Pembrolizumab Offers a Novel Perioperative Option for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Patients, Breaking Through Traditional Treatment Dilemmas! Decoding the Breakthrough Data and Clinical Implications of This Phase III Trial.